Home › Companies › Rocket Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Rocket Pharmaceuticals, Inc.’s Form 8-K, filed May 21, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 20, 2026: 10 items on Rocket Pharmaceuticals, Inc.’s Form 8-K, filed May 21, 2026: 3 approved · 7 passed (calculated).
Significant dissent: 1 director (31.8% against).
Notable dissent: 1 other board item (27.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Rocket Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Rocket Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 21, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Peter Fong, M.D. | 62,067,824 | -- | -- | 1,216,320 | 17,490,515 | 98% | Passed (calculated) | — |
| Elect Director: Carsten Boess | 62,711,345 | -- | -- | 572,799 | 17,490,515 | 99.1% | Passed (calculated) | — |
| Elect Director: Mikael Dolsten, M.D., Ph.D. | 59,500,907 | -- | -- | 3,783,237 | 17,490,515 | 94% | Passed (calculated) | — |
| Elect Director: Fady Malik, M.D., Ph.D. | 62,755,875 | -- | -- | 528,269 | 17,490,515 | 99.2% | Passed (calculated) | — |
| Elect Director: Gaurav Shah, M.D. | 62,808,593 | -- | -- | 475,551 | 17,490,515 | 99.2% | Passed (calculated) | — |
| Elect Director: David P. Southwell | 43,172,112 | -- | -- | 20,112,032 | 17,490,515 | 68% | Passed (calculated) | — |
| Elect Director: Roderick Wong, M.D. | 62,699,331 | -- | -- | 584,813 | 17,490,515 | 99.1% | Passed (calculated) | — |
| 2. Ratification of Appointment of Independent Registered Accounting Firm | 79,195,009 | 1,002,656 | 576,994 | -- | -- | 99% | Approved | — |
| 3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers | 61,389,376 | 1,671,016 | 223,752 | -- | 17,490,515 | 97% | Approved | — |
| 4. Stock Option Exchange Program | 45,582,445 | 17,615,213 | 86,486 | -- | 17,490,515 | 72% | Approved | — |
Source: Rocket Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 21, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
178 asset managers disclosed a vote on at least one Rocket Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Prior year: 98.8% for (June 18, 2025 meeting) ▲ 0.2 pts
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten Boess
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Carsten Boess”): 62,711,345 for, 572,799 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 20,507,050 for, 116,443 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,402,412 | 0 | 1 | 11,093 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 142,766 | 0 | 0 | 105,350 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Prior year: 69.9% for (June 18, 2025 meeting) ▼ 1.7 pts
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Southwell”): 43,172,112 for, 20,112,032 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 13,024,168 for, 7,599,281 withheld, 45 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,402,368 | 0 | 45 | 11,093 | For |
| State Street | 0 | 0 | 0 | 2,806,686 | Withhold |
| TIAA | 0 | 0 | 0 | 2,408,157 | Withhold |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 721,989 | Withhold |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 546,938 | Withhold |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 125,810 | 0 | 0 | 122,306 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 151,545 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 109,871 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 85,177 | Withhold |
| Global X | 0 | 0 | 0 | 80,909 | Withhold |
| ProShares | 0 | 0 | 0 | 80,431 | Withhold |
| Lincoln Financial | 17,143 | 0 | 0 | 58,701 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 65,797 | Withhold |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 58,000 | Withhold |
| American Century | 0 | 0 | 0 | 55,389 | Withhold |
| Brighthouse | 26,145 | 0 | 0 | 27,303 | Mixed |
| John Hancock | 0 | 0 | 0 | 49,130 | Withhold |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Prior year: 98.9% for (June 18, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 62,755,875 for, 528,269 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 20,510,612 for, 112,882 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,405,974 | 0 | 0 | 7,532 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 142,766 | 0 | 0 | 105,350 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Prior year: 99.1% for (June 18, 2025 meeting) ▲ 0.2 pts
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 62,808,593 for, 475,551 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 20,615,961 for, 7,532 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,405,973 | 0 | 1 | 7,532 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 248,116 | 0 | 0 | 0 | For |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Prior year: 96.1% for (June 18, 2025 meeting) ▼ 2.1 pts
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mikael Dolsten, M.D., Ph.D.”): 59,500,907 for, 3,783,237 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 18,691,800 for, 1,931,687 withheld, 8 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,409,937 | 0 | 8 | 3,562 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 721,989 | Withhold |
| Federated Hermes | 0 | 0 | 0 | 576,320 | Withhold |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,908 | 0 | 0 | 422,967 | Mixed |
| Equitable | 142,766 | 0 | 0 | 105,350 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 80,909 | Withhold |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Peter Fong, Ph.D.
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Peter Fong, M.D.”): 62,067,824 for, 1,216,320 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 20,025,554 for, 597,938 withheld, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,409,942 | 0 | 3 | 3,562 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 546,938 | Withhold |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 231,160 | 0 | 0 | 16,956 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 25,595 | 0 | 0 | 23,535 | Mixed |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Prior year: 98.8% for (June 18, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.
Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 62,699,331 for, 584,813 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 20,510,611 for, 112,882 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,405,973 | 0 | 1 | 7,532 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 142,766 | 0 | 0 | 105,350 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
72% Approved · of votes cast
Description as filed by funds: The approval of the proposed stock option exchange program; and
Rocket Pharmaceuticals, Inc.’s own tally for this item (“4. Stock Option Exchange Program”): 45,582,445 for, 17,615,213 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Four – Stock Option Exchange Program The Company's stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement.”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 14,219,383 for, 6,404,111 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,405,935 | 7,571 | 0 | 0 | For |
| State Street | 0 | 2,806,686 | 0 | 0 | Against |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 406,718 | 1,073,828 | 0 | 0 | Mixed |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 576,320 | 0 | 0 | Against |
| T. Rowe Price | 0 | 546,938 | 0 | 0 | Against |
| Bridge Builder Trust | 36,908 | 422,967 | 0 | 0 | Mixed |
| Equitable | 125,810 | 122,306 | 0 | 0 | Mixed |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 151,545 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 0 | 109,871 | 0 | 0 | Against |
| ETFis Series Trust I | 0 | 85,177 | 0 | 0 | Against |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 0 | 80,431 | 0 | 0 | Against |
| Lincoln Financial | 17,143 | 58,701 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 65,797 | 0 | 0 | Against |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 58,000 | 0 | 0 | Against |
| American Century | 0 | 55,389 | 0 | 0 | Against |
| Brighthouse | 26,145 | 27,303 | 0 | 0 | Mixed |
| John Hancock | 0 | 49,130 | 0 | 0 | Against |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 98.2% for (June 18, 2025 meeting) ▼ 0.8 pts
Description as filed by funds: A non-binding, advisory vote on the compensation of our named executive officers;
Rocket Pharmaceuticals, Inc.’s own tally for this item (“3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers”): 61,389,376 for, 1,671,016 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 Proxy Statement pursuant to Section 14…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,413,502 | 3 | 0 | 0 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 248,116 | 0 | 0 | 0 | For |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 0 | 55,389 | 0 | 0 | Against |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Fund voting reports, all 51 managers: 20,567,877 for, 55,392 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 16,734,217 | 0 | 0 | 0 | For |
| State Street | 4,323,007 | 1,698 | 0 | 0 | For |
| Newtyn Management, LLC | 2,649,999 | 0 | 0 | 0 | For |
| Nuveen | 2,433,910 | 0 | 0 | 0 | For |
| BlackRock | 2,141,108 | 173,625 | 0 | 0 | Mixed |
| MAVERICK CAPITAL LTD | 1,755,035 | 0 | 0 | 0 | For |
| AQR | 1,737,517 | 0 | 0 | 0 | For |
| DE Shaw | 1,597,419 | 0 | 0 | 0 | For |
| Two Sigma | 1,442,408 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,382,721 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 1,189,886 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 1,171,226 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,018,710 | 0 | 0 | 0 | For |
| Federated Hermes | 1,012,233 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 735,332 | 0 | 0 | Against |
| Charles Schwab | 723,522 | 0 | 0 | 0 | For |
| Vanguard | 634,900 | 0 | 0 | 0 | For |
| Goldman Sachs | 452,732 | 0 | 0 | 0 | For |
| Woodline Partners LP | 440,963 | 0 | 0 | 0 | For |
| Fidelity | 423,076 | 0 | 0 | 0 | For |
| Northern Trust | 368,610 | 0 | 0 | 0 | For |
| M28 Capital Management LP | 281,161 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 211,426 | 0 | 0 | 0 | For |
| Amitell Capital Pte Ltd | 178,769 | 0 | 0 | 0 | For |
| Rafferty Asset Management, LLC | 151,545 | 0 | 0 | 0 | For |
Institutional-manager reports, all 147 managers: 45,888,435 for, 1,002,876 against, 133,237 abstained, 900 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 99.8% for (June 18, 2025 meeting) ▼ 1.1 pts
Description as filed by funds: The ratification of the appointment of Eisner Amper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;
Rocket Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 79,195,009 for, 1,002,656 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 20,623,493 for, 1 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,413,505 | 1 | 0 | 0 | For |
| State Street | 2,806,686 | 0 | 0 | 0 | For |
| TIAA | 2,408,157 | 0 | 0 | 0 | For |
| BlackRock | 1,482,300 | 0 | 0 | 0 | For |
| Fidelity | 1,480,546 | 0 | 0 | 0 | For |
| Charles Schwab | 721,989 | 0 | 0 | 0 | For |
| Federated Hermes | 576,320 | 0 | 0 | 0 | For |
| T. Rowe Price | 546,938 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 459,875 | 0 | 0 | 0 | For |
| Equitable | 248,116 | 0 | 0 | 0 | For |
| JPMorgan | 172,900 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 151,545 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 131,134 | 0 | 0 | 0 | For |
| Dimensional | 109,871 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 85,177 | 0 | 0 | 0 | For |
| Global X | 80,909 | 0 | 0 | 0 | For |
| ProShares | 80,431 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,844 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 65,797 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,960 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 58,000 | 0 | 0 | 0 | For |
| American Century | 55,389 | 0 | 0 | 0 | For |
| Brighthouse | 53,448 | 0 | 0 | 0 | For |
| John Hancock | 49,130 | 0 | 0 | 0 | For |
| Pacific Life | 33,958 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 109,193,549 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.71% |
| 2 | State Street | 2.57% |
| 3 | TIAA | 2.21% |
| 4 | BlackRock | 1.36% |
| 5 | Fidelity | 1.36% |
| 6 | Charles Schwab | 0.66% |
| 7 | Federated Hermes | 0.53% |
| 8 | T. Rowe Price | 0.50% |
| 9 | Bridge Builder Trust | 0.42% |
| 10 | Equitable | 0.23% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 15.33% |
| 2 | State Street | 3.96% |
| 3 | Newtyn Management, LLC | 2.43% |
| 4 | Nuveen | 2.23% |
| 5 | BlackRock | 2.12% |
| 6 | MAVERICK CAPITAL LTD | 1.61% |
| 7 | AQR | 1.59% |
| 8 | DE Shaw | 1.46% |
| 9 | Two Sigma | 1.32% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.27% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Roderick Wong, M.D. | 18,428,582 | 16.88% | Proxy statement (DEF 14A), table as of March 24, 2026 |
| RTW Investments, LP | 18,188,457 | 16.66% | Proxy statement (DEF 14A), table as of March 24, 2026 |
| Vanguard Group | 8,544,423 | 7.83% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 7,834,795 | 7.18% | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,485,989 | 4.11% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 3,941,377 | 3.61% | Form 13F, quarter ended March 31, 2026 |
| Gaurav Shah, M.D. | 3,226,322 | 2.95% | Proxy statement (DEF 14A), table as of March 24, 2026 |
| Geode Capital | 2,189,256 | 2.00% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 2,169,625 | 1.99% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 1,861,116 | 1.70% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 109,193,549 shares outstanding, as reported by Rocket Pharmaceuticals, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Rocket Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2026, in the 2025-2026 proxy season, 178 asset managers reported votes on at least one of its 10 ballot items in their SEC Form N-PX filings, covering 1,813 separate fund positions. On the most widely held item on that ballot — A non-binding, advisory vote on the compensation of our named executive officers; — Rocket Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Rocket Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 21, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rocket Pharmaceuticals, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Rocket Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Rocket Pharmaceuticals (RCKT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rocket-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.